1979-96-0

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dichloro-2-Methylsulfanyl-5-nitro-pyriMidine is used as a synthetic intermediate for the development of Cathepsin K inhibition SAR (Structure-Activity Relationship). Cathepsin K is a cysteine protease enzyme that plays a crucial role in bone resorption, and its inhibition is a target for the treatment of osteoporosis and other bone-related disorders. 4,6-Dichloro-2-Methylsulfanyl-5-nitro-pyriMidine contributes to the understanding of the structure-activity relationship of Cathepsin K inhibitors, aiding in the design and synthesis of more potent and selective drugs.
Additionally, 4,6-Dichloro-2-Methylsulfanyl-5-nitro-pyriMidine is used in the synthesis of GS39783 (G797150), which is an allosteric positive modulator of GABAB receptors. GABAB receptors are metabotropic receptors that play a role in various physiological processes, including regulation of neurotransmitter release, modulation of neuronal excitability, and regulation of energy balance. Positive allosteric modulation of GABAB receptors has potential therapeutic applications in the treatment of neurological and psychiatric disorders, such as epilepsy, anxiety, and schizophrenia.

InChI:InChI=1/C5H3Cl2N3O2S/c1-13-5-8-3(6)2(10(11)12)4(7)9-5/h1H3

Upstream product

• 1979-97-1 2-(methylthio)-5-nitropyrimidine-4,6-diol 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 6632-63-9 6-chloro-2-(methylthio)pyrimidin-4-ol 

Downstream Products

• 200011-85-4 2-methylthio-4-chloro-5-nitro-6-(3-(dimethylaminocarbonyl)phenoxy)pyrimidine 
• 203925-87-5 2-methylthio-4-chloro-5-nitro-6-(2-benzyloxy-5-cyanophenoxy)pyrimidine 
• 101622-51-9 olomoucine 
• 56032-35-0 4-chloro-6-methoxy-2-(methylsulfanyl)-5-nitropyrimidine 
• 136524-28-2 9-Ethyl-7-methyl-4-(dimethylamino)-2-(methylthio)imidazo[5,1-h]-pteridin-6(5H)-one 

Relevant academic research and scientific papers

Discovery of 5-Nitro-6-thiocyanatopyrimidines as Inhibitors of Cryptococcus neoformans and Cryptococcus gattii

Opportunistic infections from pathogenic fungi present a major challenge to healthcare because of a very limited arsenal of antifungal drugs, an increasing population of immunosuppressed patients, and increased prevalence of resistant clinical strains due to overuse of the few available antifungals. Cryptococcal meningitis is a life-threatening opportunistic fungal infection caused by one of two species in the Cryptococcus genus, Cryptococcus neoformans and Cryptococcus gattii. Eighty percent of cryptococcosis diseases are caused by C. neoformans that is endemic in the environment. The standard of care is limited to old antifungals, and under a high standard of care, mortality remains between 10 and 30%. We have identified a series of 5-nitro-6-thiocyanatopyrimidine antifungal drug candidates using in vitro and computational machine learning approaches. These compounds can inhibit C. neoformans growth at submicromolar levels, are effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and are not antagonistic with currently approved antifungals.

NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947

The NO-sGC-cGMP signaling pathway plays an important role in the cardiovascular system. Loss of nitric oxide tone or impaired signaling has been associated with cardiovascular diseases, such as hypertension, pulmonary hypertension and heart failure. Direct activation of sGC enzyme independent of NO represents a novel approach for modulating NO signaling with tremendous therapeutic potential. Herein, we describe the design of a structurally novel class of heme-dependent sGC stimulators containing the 3,3-dimethylpyrrolidin-2-one moiety which resulted in the identification of the potent, selective stimulator 30 (MK-2947) for the treatment of hypertension.

Synthesis of ticagrelor analogues belonging to 1,2,3-triazolo[4,5-d]pyrimidines and study of their antiplatelet and antibacterial activity

Based on the recent observation that the antiplatelet agent ticagrelor and one of its metabolite exert bactericidal activity against gram-positive bacteria, a series of 1,2,3-triazolo[4,5-d]pyrimidines structurally related to ticagrelor were synthesized and examined as putative antiplatelet and antibacterial agents. The aim was to assess the possibility of dissociating the two biological properties and to find novel 1,2,3-triazolo[4,5-d]pyrimidines expressing antiplatelet activity and devoid of in vitro antibacterial activity. The new compounds synthesized were known metabolites of ticagrelor as well as structurally simplified analogues. Some of them were found to express antiplatelet activity and to lose the antibacterial activity, supporting the view that the two activities were not necessarily linked.

PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS

New pyrimidine derivatives of formula (I), optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. New pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

Synthetic method of 2-methylmercapto-4,6-dichloro-5-nitropyrimidine

The invention provides a synthetic method of 2-methylmercapto-4,6-dichloro-5-nitropyrimidine. The synthetic method comprises the following steps that 2-methylmercapto-4,6-dihydroxypyrimidine are addedinto nitrosonitric acid in batches, stirring is conducted at the room temperature for 1 h, reaction is conducted by heating; after reaction is completed, the temperature is lowered to the room temperature, the mixture is slowly poured into ice water and stirred for 1 h, filtering is conduced, a filter cake is washed till neutral and dug out to be dried, and a compound B is obtained; the compoundB, phosphorus oxychloride and the organic alkali are mixed for chlorination; after completion, the mixture is cooled, the extra phosphorus oxychloride are removed through vacuum concentration, after water is added for quenching, an organic solvent is used for extraction, drying and concentration are conducted, and a pure product is obtained. According to the synthetic method of the 2-methylmercapto-4,6-dichloro-5-nitropyrimidine, nitrification and chlorination are conducted on raw materials which are available in the market to generate the pure product; the raw materials are supplied by largecommercial supply, and are cheap and easy to obtain, auxiliary materials can be recycled and reused, the cost is obviously lowered, meanwhile, pollution on the environment of toxic substance in the production process is avoided, and safety in the operation process is improved; and the yield is greatly improved, the time is effectively shortened, operation is easy, and the post treatment process issimplified.

Convenient synthesis of 2-(methylsulfonyl)pyrimidine derivatives

An efficient and convenient approach for the preparation of functionalized 2-(methylsulfonyl)pyrimidine derivatives has been developed through cyclic condensation of malonate derivatives with S-methylisothiouronium sulfate followed by derivation and oxidation in water–acetone mixture using oxone as the oxidant. This synthetic strategy provides an efficient and environmentally friendly approach for easy access to 2-(methylsulfonyl)pyrimidine derivatives with considerable yields.

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

MODULATORS OF TOLL-LIKE RECEPTORS

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.